| Dr William E Cress, MD | |
|
40 W Erie St, Suite 203, Painesville, OH 44077-3274 | |
| (440) 350-0832 | |
| (440) 354-7420 |
| Full Name | Dr William E Cress |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 44 Years |
| Location | 40 W Erie St, Painesville, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346240991 | NPI | - | NPPES |
| 0524490 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 0101238872 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health Ball Memorial Hospital | Muncie, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indiana University Health Ball Memorial Physicians Inc | 9537072640 | 297 |
News Archive
QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.
BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.
Nearly one million patient-safety incidents occurred among Medicare patients over the years 2006, 2007, 2008, a figure virtually unchanged since last year's annual study of patient safety by HealthGrades, the leading independent healthcare ratings organization. In all, the incidents were associated with $8.9 billion in costs. One in ten patients - 99,180 individuals - experiencing a patient-safety incident died as a result, the study found.
The retrial of five Bulgarian nurses and a Palestinian doctor accused of knowingly infecting hundreds of Libyan children with HIV has resumed in the Libyan capital, Tripoli.
Ember Therapeutics, Inc., a Boston-based biotechnology company dedicated to the discovery and development of novel obesity and diabetic related therapies, and Mariel Therapeutics, a privately held, New York-based biotechnology company developing targeted therapies for osteoarthritis and kidney fibrosis using Bone Morphogenetic Protein (BMP)-7, jointly announce today that they have entered into a definitive agreement to merge the two companies.
› Verified 7 days ago
| Entity Name | Indiana University Health Ball Memorial Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235455544 PECOS PAC ID: 9537072640 Enrollment ID: O20031110000505 |
News Archive
QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.
BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.
Nearly one million patient-safety incidents occurred among Medicare patients over the years 2006, 2007, 2008, a figure virtually unchanged since last year's annual study of patient safety by HealthGrades, the leading independent healthcare ratings organization. In all, the incidents were associated with $8.9 billion in costs. One in ten patients - 99,180 individuals - experiencing a patient-safety incident died as a result, the study found.
The retrial of five Bulgarian nurses and a Palestinian doctor accused of knowingly infecting hundreds of Libyan children with HIV has resumed in the Libyan capital, Tripoli.
Ember Therapeutics, Inc., a Boston-based biotechnology company dedicated to the discovery and development of novel obesity and diabetic related therapies, and Mariel Therapeutics, a privately held, New York-based biotechnology company developing targeted therapies for osteoarthritis and kidney fibrosis using Bone Morphogenetic Protein (BMP)-7, jointly announce today that they have entered into a definitive agreement to merge the two companies.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William E Cress, MD 816 Independence Blvd, Suite 2a, Virginia Beach, VA 23455-6010 Ph: (757) 363-6712 | Dr William E Cress, MD 40 W Erie St, Suite 203, Painesville, OH 44077-3274 Ph: (440) 350-0832 |
News Archive
QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.
BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.
Nearly one million patient-safety incidents occurred among Medicare patients over the years 2006, 2007, 2008, a figure virtually unchanged since last year's annual study of patient safety by HealthGrades, the leading independent healthcare ratings organization. In all, the incidents were associated with $8.9 billion in costs. One in ten patients - 99,180 individuals - experiencing a patient-safety incident died as a result, the study found.
The retrial of five Bulgarian nurses and a Palestinian doctor accused of knowingly infecting hundreds of Libyan children with HIV has resumed in the Libyan capital, Tripoli.
Ember Therapeutics, Inc., a Boston-based biotechnology company dedicated to the discovery and development of novel obesity and diabetic related therapies, and Mariel Therapeutics, a privately held, New York-based biotechnology company developing targeted therapies for osteoarthritis and kidney fibrosis using Bone Morphogenetic Protein (BMP)-7, jointly announce today that they have entered into a definitive agreement to merge the two companies.
› Verified 7 days ago
Dr. Donnah W Whitaker, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7757 Auburn Rd Ste 15, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-354-7420 | |
Dr. John R Hagopian, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7590 Auburn Rd, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-579-0191 | |
Dr. Young Lee, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 40 W Erie St, Suite 203, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-354-7420 | |
Dr. John Joseph Scerbo, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7590 Auburn Rd, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-579-0191 | |
Dr. Christine Jordan, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 40 W Erie St, Suite 203, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-354-7420 | |
Dr. Paul Anders Bjorn, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7590 Auburn Rd, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-579-0191 |